Shanghai Pharma attracts strong cornerstone demand
Shanghai Pharmaceuticals Holding launched its HK$17.3bn ($2.22bn) Hong Kong IPO this week and the deal was twice covered after two days, despite the poor performance of recent IPOs and the muted investor appetite that has characterised much of the past few weeks.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts